Cogent Biosciences (COGT) EBIT: 2017-2020
Historic EBIT for Cogent Biosciences (COGT) over the last 4 years, with Dec 2020 value amounting to -$11.5 million.
- Cogent Biosciences' EBIT fell 611.43% to -$11.5 million in Q4 2020 from the same period last year, while for Dec 2020 it was -$82.2 million, marking a year-over-year decrease of 155.45%. This contributed to the annual value of -$82.2 million for FY2020, which is 155.45% down from last year.
- Per Cogent Biosciences' latest filing, its EBIT stood at -$11.5 million for Q4 2020, which was up 79.97% from -$57.2 million recorded in Q3 2020.
- Over the past 5 years, Cogent Biosciences' EBIT peaked at $2.2 million during Q4 2019, and registered a low of -$57.2 million during Q3 2020.
- Over the past 3 years, Cogent Biosciences' median EBIT value was -$10.0 million (recorded in 2018), while the average stood at -$12.5 million.
- As far as peak fluctuations go, Cogent Biosciences' EBIT skyrocketed by 124.88% in 2019, and later crashed by 611.43% in 2020.
- Over the past 4 years, Cogent Biosciences' EBIT (Quarterly) stood at -$6.9 million in 2017, then slumped by 30.87% to -$9.0 million in 2018, then skyrocketed by 124.88% to $2.2 million in 2019, then crashed by 611.43% to -$11.5 million in 2020.
- Its EBIT was -$11.5 million in Q4 2020, compared to -$57.2 million in Q3 2020 and -$7.4 million in Q2 2020.